July 2025 in “Journal of the Pakistan Medical Association” Combining TCA with 5-FU is more effective and safer for treating keloids than TCA alone.
44 citations
,
November 2022 in “Frontiers in Immunology” TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
25 citations
,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
January 1985 in “Clinical research” Topical alpha-terthienyl with UVA may safely treat psoriasis without cancer risk.
March 2023 in “JAAD case reports” 6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
August 2025 in “MedScien” Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
7 citations
,
August 2020 in “Current topics in medicinal chemistry” New cancer treatments aim to reduce side effects and improve effectiveness.
34 citations
,
January 2023 in “Therapeutic Advances in Medical Oncology” Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.
24 citations
,
January 2017 in “International Journal of Trichology”
28 citations
,
March 2017 in “Scientific Reports” Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
April 2023 in “Journal of Investigative Dermatology” Melatonin may help prevent hair loss caused by the chemotherapy drug paclitaxel.
June 2017 in “Reactions Weekly” Some breast cancer treatments caused long-term hair loss in women, similar to a condition called alopecia areata.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
January 2025 in “Nanoscale Advances” The nanocomposite effectively targets lung cancer cells without harming normal cells.
February 2026 in “International Journal of Clinical Dermatology” A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.